Study #2019-0560
A Phase 3, Randomized, Double-Blind Study Of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed By Surgical Resection And Adjuvant Treatment With Nivolumab Or Placebo For Participants With Resectable Stage II-II
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Tina Cascone
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.